focused bio venture company - JETEMA

Member for+ 1 years

Last update:

Contact - JETEMA. CO,.LTD

321, Joeom-ro, Jijeong-myeon
Wonju-si 26355

South Korea

Fax +82 2 572 1060

Latest products added

Jetema Co., Ltd. has the biggest toxin manufacturing capacity in South Korea.<br />
The toxin plant was finished with i

THE TOXIN_Botulinum Toxin

Vitten Hydro/Hydro Plus&nbsp;<br />
: for skin hydration, brightening and elasticity<br />
<br />
Vitten PN/PN Plus (

Vitten series

epiticon is an innovative and unique dual-action fixation thread<br />
1. New patented structure: each unit of epiticon

Epiticon_contouring lifting thread

Send a message - JETEMA. CO,.LTD

*Mandatory fields

Legal information - JETEMA. CO,.LTD

Nature Head Office
Year established 2009
Corporate capital 1,343,065 USD
Co.Registration No 135-86-03665
No employees (address) 120 Employees
No employees 120 Employees
Kompass ID? KR122603
Kompass member for + 1 years
Membership Booster International

Presentation - JETEMA. CO,.LTD

Hyaluronic Acid Filler,  Botulinum Toxin korea, Anti-aging Filler, contouring lifting thread, correction of facial wrinkle, biomedical material for wrinkle removal, HA Filler, injectable hyaluronic acid, facial filler in Korea, 

# Company Information 
Biopharmaceutical company based in Korea with the ultimate solution for anti-aging
- research and development of biopharmaceuticals and medical products 
- medical devices such as lasers

# Strength 
 "Best in Class" - Global Market Leader with Best Products
 "Ultra High Safety" - The World's Best Product in Quality

# Main Product
1) e.p.t.q._Hyaluronic Acid Filler
2) Epiticon_contouring lifting thread
3) THE TOXIN_Botulinum Toxin

# Video URL 
:(JETEMA's HA Filer Factory Interview)


Previous news
  • Oct 29 2019
    New product

    Jetema, developed hyaluronic acid with minimzed side effects


    Jetema strived to succeed in manufacturing filler with MoD (Degree of Modification) less than 5%, which is lower than Juvederm, the world's #1 product, with MOD of 6~8%
    Jetema succeeded in manufacutring filler with significantly less crosslinking agent, resulting in 1.89% MoD.

    Strived to develop filler's composition that prevents calicifcations from mineralization in the body. Verified no calicifications from mineralization through 2 weeks in-vitro testing of products.
    Also in biological safety test (ISO10993), no toxicity was verified, and the same efficacy was found in comparison in-vivo test with world's #1 product.

    Original text :
  • Feb 26 2019
    New office opening

    JETEMA Co., Ltd. holds ceremony for the completion of the cGMP Bio-Center in Wonju


    Location: Wonju, Gangwon-do

    Biopharmaceutical venture company JETEMA Co., Ltd. held a ceremony for the completion of the cGMP Bio-Center in Wonju, Gangwon Province on February 27.
    Followed by the completion of the first plant in Gyeonggi-do, JETEMA has completed the construction of the large-scale Bio-Center in Wonju, Gangwon-do with a land area of ​​20,860m, ​​a building area of ​​26,660m2, and a total floor area of ​​7759m2.

    JETEMA's Wonju Bio-Center is a cGMP compliant production base and has been built to meet the most stringent US Food and Drug Administration (FDA) approval standards beyond the Korea Food and Drug Administration (KFDA) standard.
    The Wonju Bio-Center has the capacity to produce more than 4 million vials annually, with the largest production capacity in Korea as a botulinum toxin single plant and the latest patented process can produce ultra high purity, highly active protein products.
    In addition, JETEMA secured Botulinum toxin A as well as B and E strains for the first time in the world, and is accelerating the development of Type B and E products for the future market. In order to expand the global Botulinum Toxin market, which is limited to type A, to type B and E, JETEMA has established a disruptive innovation strategy aimed at securing the most indications within the shortest period. For this purpose, establishment of Supply Chain Management (SCM), establishment of strategic alliances with developed countries and large domestic pharmaceutical companies are in process, enabling the first export of the BonT by the end of this year.
    In Yongin Plant I, e.p.t.q. filler is manufactured with improved safety by minimizing chemical cross-linking agents (BDDE) since the second half of 2017. It has successfully entered the domestic market last year and has started to sell in Europe after CE (European Safety Standard) certification for European distribution. e.p.t.q. is being exported worldwide to Russia, Japan, Mexico, Kazakhstan, Turkey, Iraq, Poland and Hong Kong.
  • Oct 23 2018
    Participate in an event

    JETEMA Co., Ltd. Spurred on entering global market with participation of 'INTERCHARM Moscow 2018'



    Location: Moscow, Russia

    The R&D based biopharmaceutical company, Jetema Co., Ltd.,  
    introduced the high purity HA filler e.p.t.q. (epitique) developed by its sole technology,
    lifting thread Epiticon and a total of 7 kinds of products to worldwide doctors and partners during its participation in 'INTERCHARM Moscow 2018' held in Moscow, Russia from October 24 to 27.


    see original text
More news

Company catalogues -  JETEMA. CO,.LTD

Company’s Videos -  JETEMA. CO,.LTD

General Information -  JETEMA. CO,.LTD

Export area

Central/East Europe
Poland, Germany

Brands -  JETEMA. CO,.LTD

  • e.p.t.q.  (Producer / Exporter)

    e.p.t.q. was born for women who want to manage beauty's exquisite detail.
    The hyaluronic acid filler e.p.t.q. produced according to technology and process ofJETEMA R&D center promises an exquisite and safe quality.

Location -  JETEMA. CO,.LTD

Executives -  JETEMA. CO,.LTD

Jae-yeong Kim

CEO - Chief Executive Officer